Joel Seth Hayflick

US Patent:

6479256, Nov 12, 2002

Filed:

Mar 4, 1999

Appl. No.:

09/262537

Inventors:

Joel S. Hayflick - Seattle WA

Assignee:

ICOS Corporation - Bothell WA

International Classification:

C12P 2106

US Classification:

435 691, 4352523, 4353201, 435471, 536 235

Abstract:

Disclosed are novel seven transmembrane receptor polypeptides having characteristic extracellular structure including lectin-binding, olfactomedin-like and mucin-like domains.

US Patent:

20050043239, Feb 24, 2005

Filed:

Aug 13, 2004

Appl. No.:

10/918803

Inventors:

Jason Douangpanya - Bothell WA, US
Joel Hayflick - Seattle WA, US
Kamal Puri - Lynnwood WA, US

International Classification:

A61K038/17

US Classification:

514012000

Abstract:

The present invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting undesirable immune responses without inhibiting desired immune responses. In one embodiment, the invention provides methods of inhibiting an endogenous immune response stimulated by at least one endogenous factor without substantially inhibiting an exogenous immune response stimulated by at least one exogenous factor comprising administering an amount of a phosphoinositide 3-kinase delta (PI3Kδ) selective inhibitor effective to inhibit the endogenous immune response stimulated by endogenous factor without substantially inhibiting the exogenous immune response stimulated by the at least one exogenous factor.

US Patent:

20050054614, Mar 10, 2005

Filed:

Aug 13, 2004

Appl. No.:

10/918825

Inventors:

Thomas Diacovo - St. Louis MO, US
Joel Hayflick - Seattle WA, US
Kamal Puri - Lynnwood WA, US

International Classification:

A61K031/675
A61K031/445

US Classification:

514080000, 514317000

Abstract:

The invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting leukocyte accumulation comprising selectively inhibiting phosphoinositide 3-kinase delta (PI3Kδ) activity in endothelial cells.

US Patent:

20060079538, Apr 13, 2006

Filed:

May 12, 2005

Appl. No.:

11/129006

Inventors:

Dennis Hallahan - Nashville TN, US
Joel Hayflick - Seattle WA, US
Chanchal Sadhu - Bothell WA, US

International Classification:

A61K 31/52

US Classification:

514263210

Abstract:

The invention relates generally to methods for inhibiting angiogenesis. More particularly, methods for inhibiting angiogenesis comprise selectively inhibiting phosphoinositide 3-kinase delta (PI3Kδ) activity in endothelial cells. The methods may comprise administration of one or more cytotoxic therapies including but not limited to radiation, chemotherapeutic agents, photodynamic therapies, radiofrequency ablation, anti-angiogenic agents, and combinations thereof.

US Patent:

20060106038, May 18, 2006

Filed:

May 25, 2005

Appl. No.:

11/137901

Inventors:

Didier Bouscary - Paris, FR
Joel Hayflick - Seattle WA, US
Catherine Lacombe - Paris, FR
Patrick Mayeux - Paris, FR

Assignee:

ICOS CORPORATION - Bothell WA

International Classification:

A61K 31/52

US Classification:

514263210

Abstract:

The invention relates generally to methods for treating and/or preventing aberrant proliferation of hematopoietic cells. More particularly, the invention relates to methods for treating and/or preventing aberrant proliferation of hematopoietic cells comprising selectively inhibiting phosphoinositide 3-kinase delta (PI3Kδ) activity in hematopoietic cells. The methods may be used to treat any indication involving aberrant proliferation of hematopoietic cells.

US Patent:

20080287469, Nov 20, 2008

Filed:

Feb 16, 2006

Appl. No.:

11/884566

Inventors:

Thomas G. Diacovo - New York NY, US
Joel S. Hayflick - Palo Alto CA, US
Kamal D. Puri - Lynnwood WA, US

International Classification:

A61K 31/52
A61P 29/00

US Classification:

51426321

Abstract:

The invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to methods of inhibiting leukocyte accumulation comprising selectively inhibiting phosphoinositide 3-kinase delta (PI3Kδ) and phosphoinositide 3-kinase gamma (PI3Kγ) activities in endothelial cells. The disclosed methods may be used to treat individuals having an inflammatory condition where leukocytes are found to be accumulating at the site of insult or inflamed tissue. The inflammatory condition may be attributed to or associated with an underlying disorder not typically associated with inflammation, e.g. cancer, coronary vascular disease, etc.

US Patent:

20100029693, Feb 4, 2010

Filed:

Aug 10, 2009

Appl. No.:

12/538748

Inventors:

Jason DOUANGPANYA - Bothell WA, US
Joel S. Hayflick - Seattle WA, US
Kamal D. Puri - Lynnwood WA, US

International Classification:

A61K 31/52
C07D 473/00

US Classification:

51426321, 544277

Abstract:

The present invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to specific, selective, improved PI3Kδ inhibitors and methods of inhibiting undesirable levels of PI3Kδ activity using these PI3Kδ inhibitors to treat disorders mediated by PI3Kδ.

US Patent:

60228555, Feb 8, 2000

Filed:

Sep 14, 1995

Appl. No.:

8/481534

Inventors:

Gary Thomas - Tualatin OR
Eric D. Anderson - Portland OR
Laurel Thomas - Tualatin OR
Joel S. Hayflick - Seattle WA

Assignee:

Oregan Health Sciences University - Portland OR

International Classification:

C07K 1481
C07K 412
C07K 510
A61K 3855

US Classification:

514 12

Abstract:

This invention relates to method and reagents for inhibiting furin endoprotease activity and specifically for inhibiting furin endoprotease-mediated maturation of bioactive proteins in vivo and in vitro. The invention specifically provides proteins capable of inhibiting furin endoprotease activity. Particularly provided are. alpha. sub. 1 -antitrypsin variants that specifically inhibit furin endoprotease activity. Methods for using furin endoprotease inhibition to attenuate or prevent viral protein maturation, and thereby alleviate viral infections, are provided. Also provided are methods for using furin endoprotease inhibition to attenuate or prevent proteolytic processing of bacterial toxins, thereby alleviating bacterial infections. Methods are also provided to inhibit proteolytic processing of biologically active proteins and peptides. The invention also provides pharmaceutically acceptable compositions of therapeutically effective amounts of furin endoprotease inhibitors.